Institute of Health Sciences, Medical College of Rzeszow University, 35-959 Rzeszow, Poland.
Institute of Medicine, Medical College of Rzeszow University, 35-959 Rzeszow, Poland.
Cells. 2024 Nov 14;13(22):1879. doi: 10.3390/cells13221879.
Gastrointestinal diseases are becoming a growing public health problem. One of them is inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD). The incidence of IBD is increasing in developing countries and declining in developed countries, affecting people of all ages. Researchers have been exploring new treatment options including insulin signaling pathways in the inflammation of the gastrointestinal tract. It seems that a better understanding of the mechanism of IGF-1, GLP-1 and TL1A on the gut microbiota and inflammation may provide new advances in future therapeutic strategies for patients with IBD, but also other intestinal diseases. This review aims to synthesize insights into the effects of GLP, IGF and anti-TL1A on inflammation and the gut microbiota, which may enable their future use in therapy for people with intestinal diseases.
胃肠道疾病正成为一个日益严重的公共卫生问题。其中之一是炎症性肠病（IBD），它包括溃疡性结肠炎（UC）和克罗恩病（CD）。IBD 的发病率在发展中国家呈上升趋势，在发达国家呈下降趋势，影响着所有年龄段的人群。研究人员一直在探索新的治疗选择，包括胰岛素信号通路在胃肠道炎症中的作用。更好地了解 IGF-1、GLP-1 和 TL1A 对肠道微生物群和炎症的作用机制，可能为未来 IBD 患者以及其他肠道疾病的治疗策略提供新的进展，但也可能为未来 IBD 患者以及其他肠道疾病的治疗策略提供新的进展。这篇综述旨在综合了解 GLP、IGF 和抗 TL1A 对炎症和肠道微生物群的影响，这可能使它们能够在未来用于治疗肠道疾病患者。
